文献速递心力衰竭与心肌病

机械循环支持联合免疫调节治疗暴发性心肌炎的疗效

[Efficacy of combined treatment with mechanical circulation support devices and immunomodulation therapy for patients with fulminant myocarditis].
PubMed 文献 · Zhonghua Xin Xue Guan Bing Za Zhi · 2021-01-01

该研究回顾性分析37例暴发性心肌炎合并心原性休克患者,按机械循环支持方式分为IABP组、ECMO组和IABP+ECMO组,均接受以机械循环支持和免疫调节为核心的综合治疗。结果显示34例存活出院,存活率92%,出院时LVEF较入院时改善,三组存活率差异无统计学意义。

要点

  • 以机械循环支持和免疫调节为核心的综合方案可有效救治暴发性心肌炎合并心原性休克。
  • 37例患者中34例好转出院,存活率92%,出院时LVEF为(50.1±10.5)%。
  • IABP+ECMO组乳酸水平更高、LVEF更低、机械通气比例更高,但三组存活率差异无统计学意义。

核心结论

  • 以机械循环支持和免疫调节为核心的综合救治方案可有效救治暴发性心肌炎合并心原性休克患者。

研究设计与样本

  • 该研究为观察性研究,回顾性连续入选2017年10月至2019年12月河南省人民医院心脏重症监护室收治的暴发性心肌炎合并心原性休克患者37例。
  • 根据机械辅助支持方式分为IABP组(n=19)、ECMO组(n=5)和IABP+ECMO组(n=13)。

主要发现

  • 37例患者年龄(37.4±17.0)岁,男性22例,入院时平均动脉血压(70.21±17.37)mmHg,心率(100±30)次/min。
  • 37例中死亡3例(均为IABP+ECMO组患者),其余34例好转出院,存活率92%,住院天数(22.7±8.2)d,出院时LVEF(50.1±10.5)%。
  • IABP+ECMO组乳酸水平高于IABP组和ECMO组(P<0.001和=0.005),LVEF低于IABP组(P=0.004),机械通气比例高于IABP组和ECMO组(P分别为0.005和0.022)。
  • 三组患者存活比例差异无统计学意义(χ²=4.614,P=0.079)。

关键数值与推荐

  • 采用相关共识推荐的「以生命支持为依托的综合救治方案」治疗,主要包括机械循环支持(如IABP不足以维持循环,应立刻加用ECMO)和免疫调节治疗(包括使用足够剂量的糖皮质激素和免疫球蛋白)。
  • 免疫调节治疗包括糖皮质激素(甲泼尼龙)和静脉注射免疫球蛋白。
  • 三度房室传导阻滞10例均植入临时起搏器,室性心动过速/心室颤动12例,因交感电风暴植入临时起搏器1例。

临床怎么用

  • 对暴发性心肌炎合并心原性休克患者,可采用以机械循环支持和免疫调节为核心的综合救治方案。
  • IABP不足以维持循环时应立刻加用ECMO。
  • 免疫调节治疗包括足够剂量的糖皮质激素和免疫球蛋白。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To summarize the efficacy of combined treatment strategy of mechanical circulation support devices and immunomodulation therapy for patients with fulminant myocarditis. Method: We retrospectively analyzed the clinical data and outcomes of 37 fulminant myocarditis patients complicating cardiogenic shock, who were hospitalized from October 2017 to December 2019 in our department. Patients received guideline therapy according to "Chinese expert consensus statement on clinical diagnosis and treatment of fulminant myocarditis in adults"issued by Chinese Society of Cardiology of Chinese Medical Association. Patients were divided into IABP group (n=19), ECMO group (n=5) and IABP+ECMO group (n=13) according to different mechanical circulation support regimen. The treatment effectiveness among various groups were compared. The major endpoint was in-hospital mortality. The duration and outcome of mechanical circulation support were also analyzed. Furthermore, relationships between baseline data, proportion of different treatments (including medicine treatment, temporary pacemaker and continuous renal replacement treatment, immunomodulation therapy) and clinical outcome were analyzed. Results: The age of the 37 patients in the cohort was (37.4±17.0) years, and there were 22 male among them. Immunomodulation therapy included glucocorticoid (methylprednisolone) and intravenous immunoglobin. At admission, blood pressure was (70.21±17.37)mmHg(1 mmHg=0.133 kPa),heart rate was(100±30)beat/minutes,there were 10 cases of Ⅲ° atrioventricular block and all received temporary pacemaker implantation, 12 cases of ventricular tachycardia and fibrillation,1 patient received temporary pacemaker implantation due to electronic storm, peak cardiac troponin I level was (18.61±9.55)μg/L, peak B type natriuretic peptide level was 1 670(518,3 410)ng/L,left ventricular ejection fraction (LVEF) was(32.3±10.4)%. Thirty-four out of the 37 patients survived and 3 patients died. Hospital duration was (22.7±8.2)days, LVEF was (50.1±10.5)% at discharge. Lactic acid level was significantly higher in IABP+ECMO group than in IABP group and ECMO group(P<0.001 or =0.005),LVEF was significantly lower in IABP+ECMO group than in IABP group(P=0.004),the proportion of ventilator usage was higher in IABO+ECMO group than in IABP group (P<0.05). Survival rate was similar among the three groups. Conclusion: Comprehensive treatment regimen with combined mechanical circulation support and immunomodulation therapy as the core strategies is effective in the treatment of fulminant myocarditis complicated with cardiogenic shock. 目的: 总结机械循环支持和免疫调节联合治疗暴发性心肌炎合并心原性休克患者的疗效。 方法: 该研究为观察性研究。回顾性连续入选2017年10月至2019年12月河南省人民医院心脏重症监护室收治的暴发性心肌炎合并心原性休克的患者。根据机械辅助支持的方式将入选患者分为主动脉内球囊反搏(IABP)组、体外膜肺氧合(ECMO)组和IABP+ECMO组。采用相关共识推荐的“以生命支持为依托的综合救治方案”治疗,主要包括机械循环支持(如IABP不足以维持循环,应立刻加用ECMO),免疫调节治疗(包括使用足够剂量的糖皮质激素和免疫球蛋白),如果患者合并呼吸窘迫应立即给予机械通气,其他治疗包括对症和预防使用抗生素治疗。采用电子和手工检索结合的方法从医院病历系统中获得入选患者的临床资料,包括基线临床资料,药物治疗情况,临时起搏器、连续肾脏替代治疗及机械通气使用情况,以及主要治疗结果[包括死亡、好转情况,住院天数,以及出院时左心室射血分数(LVEF)值等]等。 结果: 研究共入选患者37例,其中男性22例,年龄(37.4±17.0)岁。37例患者中19例单用IABP支持治疗(IABP组),5例直接采用ECMO支持治疗(ECMO组),其余13例采用了IABP+ECMO支持治疗(IABP+ECMO组)。37例患者入院时平均动脉血压为(70.21±17.37)mmHg(1 mmHg=0.133 kPa),心率(100±30)次/min,三度房室传导阻滞10例、室性心动过速/心室颤动12例,其中由于三度房室传导阻滞植入临时起搏器者10例,由于交感电风暴植入临时起搏器者1例。37例患者入院时峰值心肌肌钙蛋白I(18.61±9.55)μg/L,峰值B型利钠肽1 670(518,3 410)ng/L,LVEF(32.3±10.4)%。37例患者中死亡3例(均为IABP+ECMO组患者),其余34例均好转出院,存活率92%,且均可下床活动并正常饮食,住院天数(22.7±8.2)d。出院时34例患者的LVEF为(50.1±10.5)%。IABP+ECMO组患者乳酸水平高于IABP组和ECMO组(P<0.001和=0.005),LVEF低于IABP组(P=0.004),三组患者存活比例差异无统计学意义(χ²=4.614,P=0.079)。IABP+ECMO组患者机械通气比例高于IABP组和ECMO组(P分别为0.005和0.022),血管活性药物使用情况、植入临时起搏器比例、行连续肾脏替代治疗比例三组间差异无统计学意义(P均>0.05)。 结论: 以机械循环支持和免疫调节为核心的综合救治方案可有效救治暴发性心肌炎合并心原性休克患者。.

来源:Zhonghua Xin Xue Guan Bing Za Zhi,查看原文。版权归原作者所有。

引用

  1. Ye FM, Zhang JJ, Wang BB, et al. [Efficacy of combined treatment with mechanical circulation support devices and immunomodulation therapy for patients with fulminant myocarditis]. Zhonghua Xin Xue Guan Bing Za Zhi. 2021. PMID: 34530597. doi:10.3760/cma.j.cn112148-20201214-00985

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。